caa a22 4500 397591543 CHVBK 20180308164940.0 cr unu---uuuuu 161202e199612 xx s 000 0 eng 10.1093/jac/38.6.953 doi (NATIONALLICENCE)oxford-10.1093/jac/38.6.953 Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies [Elektronische Daten] [A. Böhme, G. Just-Nübling, L. Bergmann, P. M. Shah, W. Stille, D. Hoelzer] The efficacy of oral itraconazole 2 × 200 mg capsules daily for prevention of systemic mycoses was investigated in granulocytopenic patients with haematological malignancies. Of 241 patients, 197 were evaluable for prophylactic efficacy, and 214 for adverse events. Patients with similar characteristics receiving oral amphotencin B as antifungal prophylaxis, observed over 15 months before introduction of itraconazole, served as control group (n = 223). With itraconazole prophylaxis, 13 cases of aspergillosis (9 proven, 1 probable, 3 possible; 7%) and no systemic yeast infection occurred, compared with 14 episodes of aspergillosis (9 proven, 2 probable, 3 possible; 6%) and 3 proven systemic yeast infections (Candida albicans, Candida norvegensis, Trichosporon beigelii) in the historical group. Adverse events were observed in 13% of evaluable patients receiving itraconazole. In four patients with acute lymphoblastic leukaemia receiving itraconazole and vincristine simultaneously, severe vinca alkaloid-induced neurotoxicity occurred. Plasma concentrations of itraconazole and hydroxyitraconazole were measured in 64 patients. After eight days of itraconazole the median drug concentration was adequate (700 ng/mL), but there was a marked individual variation (229-2861 ng/mL). In comparison with a historical group, antifungal prophylaxis with itraconazole reduced the incidence of systemic yeast infections, but the frequency of aspergillosis was similar. However, a general increasing incidence of aspergillus infections at our hospital over the last four years should be considered in the assessment of study results. © 1996 by the British Society for Antimicrobial Chemotherapy Original articles nationallicence Böhme A. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Just-Nübling G. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Bergmann L. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Shah P. M. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Stille W. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Hoelzer D. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/6(1996-12), 953-961 0305-7453 38:6<953 1996 38 jac https://doi.org/10.1093/jac/38.6.953 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.6.953 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Böhme A. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 700 1- Just-Nübling G. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 700 1- Bergmann L. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 700 1- Shah P. M. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 700 1- Stille W. Medical Clinic III, Infectious Diseases Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 700 1- Hoelzer D. Medical Clinic III, Haematology/Oncology, J. W. Goethe-University Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/6(1996-12), 953-961 0305-7453 38:6<953 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford